Fate Therapeutics

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Fate Therapeutics reports strong financials, advances innovative CAR cell therapies

Fate Therapeutics reported strong financial performance with a focus on advancing key programs and innovative CAR NK and CAR T-cell products.
The company faces challenges in managing costs post-collaboration termination and navigating increased research and development expenses.
Opportunities lie in advancing IND submissions, exploring novel therapy combinations, and enhancing transparency through data disclosures and collaboration.
Overall, Fate Therapeutics showcases strength in leveraging proprietary platforms for differentiated therapies and commitment to advancing next-gen CAR T-cell products.

Fate Therapeutics reports robust Q1 revenue growth and strategic focus

Fate Therapeutics reported strong Q1 revenue growth but faces challenges with workforce reduction and disclosure commitments
The company's financial position is robust, with a focus on advancing key CAR NK and CAR T-cell programs in 2023
Opportunities lie in exploring autoimmune applications, biomarker evaluation, and ADR technology superiority for future growth
Navigating FDA requirements and study design complexities remain key challenges for program advancement

Fate Therapeutics navigates revenue challenges, advances CAR cell programs

Fate Therapeutics faced revenue challenges in Q2 but maintained a strong financial position with significant cash reserves.
Progress in advancing CAR-NK and CAR-T cell programs signals potential growth opportunities in the oncology space.
Clear guidance on operating expenses and strategic IND submissions demonstrate a proactive approach to future growth.
Addressing revenue diversification, cost management, and effective clinical development will be key focus areas for sustained success.

Fate Therapeutics advances innovative cell therapies amidst financial stability

Fate Therapeutics demonstrated strong progress in product development and financial management, positioning them as a leader in innovative cell therapies.
While facing challenges in revenue dynamics and managing expenses, the company has opportunities to drive value through upcoming milestones and pioneering treatment approaches.
Clear communication, strategic partnerships, and a focus on clinical proof of concept will be crucial for Fate Therapeutics to navigate the competitive landscape and capitalize on opportunities for growth.
The company's commitment to advancing novel therapies in oncology and autoimmunity underscores their dedication to addressing unmet medical needs and shaping the future of patient care.

Fate Therapeutics reports solid financials, eyes autoimmune therapy expansion

Fate Therapeutics showcases strong financial position but faces expense challenges.
Their off-the-shelf cell therapy programs exhibit promising efficacy and safety profiles.
Opportunities lie in expanding clinical investigations and exploring autoimmune indications.
Challenges include high operating expenses and the need for therapy differentiation.

Fate Therapeutics excels in autoimmune therapy innovation amidst financial stability

Fate Therapeutics showcased strong performance in Q1 2024 with promising data from FT819 and FT522 programs in autoimmune diseases.
While facing high operating expenses, the company maintains financial stability and aims for continued growth and innovation in cellular therapy.
Challenges in differentiation and clinical translation are met with opportunities for expanded indications and novel treatment approaches in autoimmune settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Century Therapeutics

Novo Integrated Sciences, Inc.

Synaptogenix

Bio-Techne

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

5 Health Care Stocks That Are Diving - And May Rally

BENSALEM, Pa.--( BUSINESS WIRE )--Law Offices of Howard G. Smith continues its investigation on behalf of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) investors concerning the Company's possible violations of federal securities laws.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

Alset EHome International

CymaBay Therapeutics

Hall of Fame Resort & Entertainment

P3 Health Partners Inc

Avidity Biosciences

Summit Therapeutics

Trean Insurance Group

Viking Therapeutics

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

5 Best and Worst Performing Small-Cap Stocks in Dec 2022

LOS ANGELES--( BUSINESS WIRE )--The Law Offices of Frank R. Cruz continues its investigation of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

Boston, Massachusetts--(Newsfile Corp. - January 17, 2023) - Block & Leviton is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) for potential securities law violations. Investors who have lost money in their Fate Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/fate.What is this all about?After the market closed on January 5, 2023, Fate Therapeutics, Inc.

Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

San Francisco, California--(Newsfile Corp. - January 13, 2023) - Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now.Visit: https://www.hbsslaw.com/investor-fraud/FATEContact An Attorney Now: FATE@hbsslaw.com844-916-0895Fate Therapeutics, Inc. (FATE) Investigation: The investigation focuses on Fate's widely touted collaboration agreement with Janssen Biotech, pursuant to which Janssen and Fate agreed to collaborate to develop iPSC-derived CAR-NK and CAR T-cell product candidates

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

Los Angeles, California--(Newsfile Corp. - January 12, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fate Therapeutics, Inc. ("Fate" or "the Company") (NASDAQ: FATE) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--( BUSINESS WIRE )--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) on behalf of Fate stockholders. Our investigation concerns whether Fate has violated the federal securities laws and/or engaged in other unlawful business practices.

FATE ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Fate Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--( BUSINESS WIRE )--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) investors concerning the Company's possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

BENSALEM, Pa.--( BUSINESS WIRE )--Law Offices of Howard G. Smith announces an investigation on behalf of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) investors concerning the Company's possible violations of federal securities laws.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

LOS ANGELES--( BUSINESS WIRE )--The Law Offices of Frank R. Cruz announces an investigation of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

Los Angeles, California--(Newsfile Corp. - January 11, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fate Therapeutics, Inc. ("Fate" or "the Company") (NASDAQ: FATE) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - January 10, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fate Therapeutics, Inc. ("Fate" or "the Company") (NASDAQ: FATE) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Graphite Bio

Third Harmonic Bio Inc

Vera Therapeutics

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fate Therapeutics, Inc. (“Fate” or “the Company”) (NASDAQ: FATE) for violations of the securities laws.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Tcr2 Therapeutics

Layoffs have been making headlines so far in 2023, even though we're just a few days into the new year. That's true even for gene-editing stocks.

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC

FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.

FATE To End Janssen Deal and Prioritize Pipeline Development

Fate Therapeutics (NASDAQ: FATE ) stock is falling hard on Friday after the company announced the termination of its collaboration with Janssen Biotech. Janssen was seeking to continue its collaboration with Fate Therapeutics with revised terms and conditions.

Why Is Fate Therapeutics (FATE) Stock Down 62% Today?

Tesla

The Nasdaq Composite once again is underperforming the rest of the market.

Tesla Falls Again, but This Nasdaq Stock Is Truly Plunging

Shares of Fate Therapeutics Inc. FATE, -1.08% plunged 56.8% in premarket trading, putting them on track for a record one-day selloff, after the biopharmaceutical company announced the termination of its collaboration with Janssen Biotech Inc. and announced job cuts. The company said it had declined Janssen's proposal to continue the collaboration on “revised terms and conditions.

Fate Therapeutics stocks heads for record selloff after Janssen collaboration terminated and job cuts

Fate Therapeutics says it will reduce its work force by about 220 employees and discontinue clinical development of several cell programs.

Fate Stock Sinks. Analysts Downgrade Shares on End to Janssen Collaboration and Layoffs.

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

Iovance Biotherapeutics

Sabine Royalty Trust

After ending 2022 on a low note, U.S. market indexes continued to sink on Thursday morning after jobs data showed the labor market is still hot despite the Federal Reserve's attempts to curb inflation. According to CNBC, the ADP private payrolls report indicated employers added 235,000 jobs in December, which was higher than economists' estimates.

3 Graham's Lost Formula Picks to Consider for the New Year

Fate Therapeutics (FATE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Fate Therapeutics Stock (FATE)